Oxycodone for pain management in the latent phase of labour - A pragmatic trial.
analgesia
labour
latent phase
newborn
opioid
oxycodone
oxymorphone
Journal
Acta anaesthesiologica Scandinavica
ISSN: 1399-6576
Titre abrégé: Acta Anaesthesiol Scand
Pays: England
ID NLM: 0370270
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
29
08
2019
revised:
22
11
2019
accepted:
02
01
2020
pubmed:
18
1
2020
medline:
22
5
2021
entrez:
18
1
2020
Statut:
ppublish
Résumé
Parenteral opioids are used for pain relief in labour but there are little data for oxycodone in this context. The aim of this study was to evaluate the efficacy, foetal exposure and safety of subcutaneous oxycodone in the latent phase of labour. This pragmatic trial included 76 parturients, who received subcutaneous oxycodone for pain relief in the latent phase of labour according to the hospital protocol: an initial dose 0.1 mg/kg, and a second dose, 0.05 mg/kg, could be administered four hours later. Pain intensity and pain relief were assessed using a numerical rating scale of 0-10. After delivery, blood samples from the maternal and umbilical veins were collected, and plasma concentrations of oxycodone and its main metabolites were quantified using UPLC-MS/MS. The Apgar scores and maternal and neonatal adverse effects were recorded. The foetal exposure at birth was low, the median oxycodone and oxymorphone umbilical vein plasma concentrations were 1.2 ng/mL (range 0.21-7.8) and 0.14 ng/mL (0-0.26), respectively. Pain scores decreased substantially, from a median pain score of 7/10 before oxycodone to median scores of 5/10 at 30 minutes after administration, 5/10 at 60 minutes and 6/10 at 120 minutes. The median Apgar score was 9 (range 2-10) at 1 minute and 9 (6-10) at 5 minutes. Maternal adverse effects were mild, and there were no oxycodone-related neonatal adverse effects. Subcutaneous oxycodone provided effective analgesia during the latent phase of labour. Newborn exposure at birth was low, and oxycodone was well-tolerated.
Sections du résumé
BACKGROUND
Parenteral opioids are used for pain relief in labour but there are little data for oxycodone in this context. The aim of this study was to evaluate the efficacy, foetal exposure and safety of subcutaneous oxycodone in the latent phase of labour.
METHODS
This pragmatic trial included 76 parturients, who received subcutaneous oxycodone for pain relief in the latent phase of labour according to the hospital protocol: an initial dose 0.1 mg/kg, and a second dose, 0.05 mg/kg, could be administered four hours later. Pain intensity and pain relief were assessed using a numerical rating scale of 0-10. After delivery, blood samples from the maternal and umbilical veins were collected, and plasma concentrations of oxycodone and its main metabolites were quantified using UPLC-MS/MS. The Apgar scores and maternal and neonatal adverse effects were recorded.
RESULTS
The foetal exposure at birth was low, the median oxycodone and oxymorphone umbilical vein plasma concentrations were 1.2 ng/mL (range 0.21-7.8) and 0.14 ng/mL (0-0.26), respectively. Pain scores decreased substantially, from a median pain score of 7/10 before oxycodone to median scores of 5/10 at 30 minutes after administration, 5/10 at 60 minutes and 6/10 at 120 minutes. The median Apgar score was 9 (range 2-10) at 1 minute and 9 (6-10) at 5 minutes. Maternal adverse effects were mild, and there were no oxycodone-related neonatal adverse effects.
CONCLUSION
Subcutaneous oxycodone provided effective analgesia during the latent phase of labour. Newborn exposure at birth was low, and oxycodone was well-tolerated.
Substances chimiques
Analgesics, Opioid
0
Oxycodone
CD35PMG570
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
685-690Informations de copyright
© 2020 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Floris L, Irion O. Association between anxiety and pain in the latent phase of labour upon admission to the maternity hospital: a prospective, descriptive study. J Health Psychol. 2015;20:446-455.
Dimitraki M, Tsikouras P, Manav B, et al. Evaluation of the effect of natural and emotional stress of labor on lactation and breast-feeding. Arch Gynecol Obstet. 2016;293:317-328.
Maimburg RD, Vaeth M. Postpartum depression among first-time mothers - results from a parallel randomised trial. Sex Reprod Healthc. 2015;6:95-100.
Arendt KW, Tessmer-Tuck JA. Nonpharmacologic labor analgesia. Clin Perinatol. 2013;40:351-371.
Scotland GS, McNamee P, Cheyne H, Hundley V, Barnett C. Women’s preferences for aspects of labor management: results from a discrete choice experiment. Birth. 2011;38:36-46.
Smith LA, Burns E, Cuthbert A. Parenteral opioids for maternal pain management in labour. Cochrane Database Syst Rev. 2018;6:CD007396.
Markley JC, Rollins MD. Non-neuraxial labor analgesia: options. Clin Obstet Gynecol. 2017;60:350-364.
Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet. 2019;58:705-725.
International Narcotics Control Board. Narcotic drugs - Estimated world requirements for 2019 - Statistics for 2017. 2018. www.incb.org. Accessed June 2019, 28.
Hodge CH. Oxycodone in labour. BJOG. 1965;72:630-633.
Kokki M, Franco MG, Raatikainen K, et al. Intravenous oxycodone for pain relief in the first stage of labour - maternal pharmacokinetics and neonatal exposure. Basic Clin Pharmacol Toxicol. 2012;111:182-188.
Huuskonen P, Keski-Nisula L, Heinonen S, et al. Kuopio birth cohort - design of a Finnish joint research effort for identification of environmental and lifestyle risk factors for the wellbeing of the mother and the newborn child. BMC Pregnancy Childbirth. 2018;18:381.
Rota A, Antolini L, Colciago E, Nespoli A, Borrelli SE, Fumagalli S. Timing of hospital admission in labour: latent versus active phase, mode of birth and intrapartum interventions. A correlational study. Women Birth. 2018;31:313-318.
McQuay H, Moore A. An Evidence-Based Resource for Pain Relief. Oxford, UK: Oxford University Press; 1998.
Apgar V. The role of the anesthesiologist in reducing neonatal mortality. N Y State J Med. 1955;55:2365-2368.
Amiel-Tison C, Barrier G, Shnider SM, Levinson G, Hughes SC, Stefani SJ. A new neurologic and adaptive capacity scoring system for evaluating obstetric medications in full-term newborns. Anesthesiology. 1982;56:340-350.
Kokki M, Välitalo P, Kuusisto M, et al. Central nervous system penetration of oxycodone after intravenous and epidural administration. Br J Anaesth. 2014;112:133-140.
American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus no. 1: safe prevention of the primary cesarean delivery. Obstet Gynecol. 2014;123:693-711.
Krishnamurthy RB, Upton RN, Fajumi AO, et al. Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. Anaesth Intensive Care. 2012;40:269-274.
Olkkola K, Hamunen K, Seppälä T, Maunuksela E. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol. 1994;38:71-76.
Välitalo P, Kokki M, Ranta VP, Olkkola KT, Hooker AC, Kokki H. Maturation of oxycodone pharmacokinetics in neonates and infants: a population pharmacokinetic model of three clinical trials. Pharm Res. 2017;34:1125-1133.
Kinnunen M, Kokki H, Hautajärvi H, et al. Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe. Acta Obstet Gynecol Scand. 2018;97:1200-1205.
Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004;24:468-476.
Kendrick DB, Strout TD. The minimum clinically significant difference in patient-assigned numeric scores for pain. Am J Emerg Med. 2005;23:828-832.
Labor S, Maguire S. The pain of labour. Rev Pain. 2008;2(2):15-19.
Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE, Raeder J. A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. Anesth Analg. 2009;109:1279-1283.
Räisänen S, Kokki M, Kokki H, Gissler M, Kramer MR, Heinonen S. The use of epidural analgesia for intrapartum pain relief in publicly funded healthcare. Acta Anaesthesiol Scand. 2014;58:291-297.